Please assess the completion status of the following clinical trial:

Trial Title: Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Female, ≥ 40 years of age at screening (inclusive)~2. Reported more than 7-8 moderate to severe hot flashes per day (average) or 50-60 moderate to severe hot flashes per week for at least 30 days prior to the screening visit~3. Spontaneous amenorrhea for at least 12 consecutive months or~4. Amenorrhea for at least 6 months and meet the biochemical criteria for menopause or~5. Bilateral salpingo-oophorectomy ≥ 6 weeks with or without hysterectomy~Exclusion Criteria:~1. Known non-responder to previous Selective serotonin reuptake inhibitor (SSRI) or Serotonin norepinephrine reuptake inhibitor (SNRI) treatment for VMS~2. History of self injurious behavior~3. History of clinical diagnosis of depression or treatment for depression~4. History of clinical diagnosis of borderline personality disorder~5. Use of an investigational study medication within 30 days prior to screening or during the study~6. Concurrent participation in another clinical trial or previous participation in this trial~7. Family of investigational-site staff

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Brisdelle (paroxetine mesylate) (Type: EXPERIMENTAL): Brisdelle (paroxetine mesylate)
- Placebo Capsules (Type: PLACEBO_COMPARATOR): Placebo Capsules

Based on this trial design, predict the completion outcome and termination type (if applicable).